374 related articles for article (PubMed ID: 17671123)
1. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer.
Als AB; Dyrskjøt L; von der Maase H; Koed K; Mansilla F; Toldbod HE; Jensen JL; Ulhøi BP; Sengeløv L; Jensen KM; Orntoft TF
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4407-14. PubMed ID: 17671123
[TBL] [Abstract][Full Text] [Related]
2. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.
Jessen C; Agerbaek M; Von Der Maase H
Acta Oncol; 2009; 48(3):411-7. PubMed ID: 18798018
[TBL] [Abstract][Full Text] [Related]
4. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
5. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma.
Fromont G; Rouprêt M; Amira N; Sibony M; Vallancien G; Validire P; Cussenot O
Eur Urol; 2005 Nov; 48(5):764-70. PubMed ID: 16126329
[TBL] [Abstract][Full Text] [Related]
6. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract.
Nakanishi K; Tominaga S; Hiroi S; Kawai T; Aida S; Kasamatsu H; Aurues T; Hayashi T; Ikeda T
Virchows Arch; 2002 Dec; 441(6):559-63. PubMed ID: 12461612
[TBL] [Abstract][Full Text] [Related]
7. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L
Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875
[TBL] [Abstract][Full Text] [Related]
8. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder.
Hussain SA; Ganesan R; Hiller L; Cooke PW; Murray P; Young LS; James ND
Oncol Rep; 2003; 10(3):571-6. PubMed ID: 12684626
[TBL] [Abstract][Full Text] [Related]
9. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
10. Expression and clinical significance of CD147 in genitourinary carcinomas.
Han ZD; He HC; Bi XC; Qin WJ; Dai QS; Zou J; Ye YK; Liang YX; Zeng GH; Zhu G; Chen ZN; Zhong WD
J Surg Res; 2010 May; 160(2):260-7. PubMed ID: 19286191
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients.
Chen P; Li J; Ge LP; Dai CH; Li XQ
Respirology; 2010 Apr; 15(3):501-9. PubMed ID: 20210890
[TBL] [Abstract][Full Text] [Related]
12. EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer.
Ju XZ; Yang JM; Zhou XY; Li ZT; Wu XH
Clin Cancer Res; 2008 Jan; 14(2):494-501. PubMed ID: 18223224
[TBL] [Abstract][Full Text] [Related]
13. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.
Kim JG; Ryoo BY; Park YH; Kim BS; Kim TY; Im YH; Kang YK
Cancer Chemother Pharmacol; 2008 Feb; 61(2):301-7. PubMed ID: 17429626
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy.
Yoshida S; Saito K; Koga F; Yokoyama M; Kageyama Y; Masuda H; Kobayashi T; Kawakami S; Kihara K
BJU Int; 2008 Apr; 101(8):978-81. PubMed ID: 18190628
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
[TBL] [Abstract][Full Text] [Related]
17. Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer.
Bria E; Visca P; Novelli F; Casini B; Diodoro MG; Perrone-Donnorso R; Botti C; Sperduti I; Facciolo F; Milella M; Cecere FL; Cognetti F; Mottolese M
Eur J Surg Oncol; 2008 May; 34(5):593-8. PubMed ID: 17693049
[TBL] [Abstract][Full Text] [Related]
18. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
[TBL] [Abstract][Full Text] [Related]
19. CD147 overexpression allows an accurate discrimination of bladder cancer patients' prognosis.
Afonso J; Longatto-Filho A; Baltazar F; Sousa N; Costa FE; Morais A; Amaro T; Lopes C; Santos LL
Eur J Surg Oncol; 2011 Sep; 37(9):811-7. PubMed ID: 21733655
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.
Lin CC; Hsu CH; Huang CY; Tsai YC; Huang KH; Cheng AL; Pu YS
Urology; 2007 Mar; 69(3):479-84. PubMed ID: 17382149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
